Please use this identifier to cite or link to this item:
|Scopus||Web of Science®||Altmetric|
|Title:||Exclusion of biglycan mutations in a cohort of patients with neuromuscular disorders|
|Citation:||Neuromuscular Disorders, 2008; 18(8):606-609|
|Publisher:||Pergamon-Elsevier Science Ltd|
|Rachel A. Peat, Jozef Gécz, Justin R. Fallon, Patrick S. Tarpey, Raffaella Smith, Andrew Futreal, Michael R. Stratton, Shireen R. Lamandé, Nan Yang and Kathryn N. North|
|Abstract:||Biglycan has been considered a good candidate for neuromuscular disease based on direct interactions with collagen VI and α-dystroglycan, both of which are linked with congenital muscular dystrophy (CMD). We screened 83 patients with CMD and other neuromuscular disorders and six controls for mutations and variations in the biglycan sequence. We identified a number of novel sequence variations. After family analysis and control screening we found that none of these polymorphisms were disease-causing mutations. Thus mutations in biglycan are not a common cause of neuromuscular disorders in our cohort.|
|Keywords:||Congenital muscular dystrophy; Biglycan; α-Dystroglycan; Collagen VI|
|Description:||Copyright © 2008 Elsevier B.V. All rights reserved.|
|Appears in Collections:||Paediatrics publications|
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.